UNSPSC 51313307: Promethazine teoclate

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5PUP23U26, chemically known as 8-chloro-3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione compd. with n,n,alpha-trimethyl-10h-phenothiazine-10-ethanamine (1:1) but more generally known as promethazine teoclate, which bears US NIH Compound Identifier 63030.

UNSPSC 51313307 Promethazine teoclate is a Commodity code that nominally covers a single pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with the code's specificity — the posted opportunities involve naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products, none of which are promethazine teoclate. State and local governments do use UNSPSC pharmaceutical codes to source individual drugs and broader pharmaceutical categories, but the three recent opportunities in the block suggest either broad tagging misalignment or use of this code as a catch-all for pharmaceutical procurement activity rather than specific sourcing of promethazine teoclate. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, with participation from Oregon). The scope spans individual naloxone and safe drug deactivation system purchase, exploratory direct-to-manufacturer contracting frameworks, and standing-offer agreements for generic multi-source pharmaceuticals distributed through authorized wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023 (note: deadline appears backdated in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, as preliminary market intelligence for a Therapeutic Pharmacy Initiative direct-to-manufacturer program with no formal evaluation criteria or award values stated at that stage. The Minnesota MMCAP RFP S1070000015802, posted January 20, 2026, established multiple standing contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The MMCAP solicitation weighted price competitiveness at 75 percent and required cGMP and DSCSA compliance, vendor insurance of at least $5,000,000 commercial general liability and $2,000,000 network security and privacy liability, and a 3 percent administrative fee on all purchases.